Been watching this lately as it has been appearing in my scans. The trading volume appears to have been quite consistent in recent weeks and trend of higher lows is encouraging.
The close above the 10 EMA is a cue to buy and target the resistance above.
Jubilee Metals has corrected lower in recent weeks to retest the breakout level of 2.80p and slightly below this at the 61.8% Fibonacci support level. The large reversal today is an encouraging sign which the shares set to close above the 10EMA. It’s also been noted that trading volume has been consistently above 50k for the past 90 days. It looks an interesting...
dotdigital Group plc is a leading provider of email marketing and omnichannel SaaS technology to empower digital marketing professionals. Our marketing automation platform is used by over 70,000 marketers in 156 countries worldwide, empowering global marketers to achieve outstanding results with superior tools and services.
The shares have completed a...
Bidstack bridges the gap between gamers, game developers, and advertisers by enhancing the gaming experience with rich, real-world advertising.
The shares have risen impressively over the past couple of years and following a period of consolidation that trend looks set to continue.
We have seen the shares break higher from an ending wedge formation and...
This is an investment for me but i still like to look at the charts and hence why im looking at the weekly
Price looks like it is coiling up and has retraced approximately 50% from the highs. I think there is a high probability we we will see the all time highs broken this year with 8-8.5p being reached as a minimum
Good news flow due on there current assets and...
TRD has been in an rising channel for 6 years. The high of Dec 16/Jan 17 touched the top of the channel and resulted in a pull back and consolidation of 18 months. Price has reacted to the channel and formed a rounded bottom/cup. Likely outcomes are to form a 'handle' for the cup, or for price to move straight up, targeting the upper channel boundary.
Prudent Drug Discovery Company
Low market cap (appox £13m at time of writing).
Issues shares very rarely (last placing nearly four years ago).
Has material interest in its work from larger partners (Pharmaxis).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest...